Trial reportClinical cardiology2026
Catheter Ablation for Frequent Premature Ventricular Contractions or Paroxysmal Supraventricular Tachycardia With Vagal Bradycardia: A New Clinical Application of Superior Vena Cava-Aorta Ganglionated Plexus Modification.
Trial report in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFrequent premature ventricular contractions (PVCs) or paroxysmal supraventricular tachycardia (PSVT) in patients with bradyarrhythmia is difficult to treat. Cardioneuroablation (CNA) is now considered a promising treatment for vagally mediated bradyarrhythmia. HYPOTHESIS: Modifying the right atrial superior vena cava-aorta ganglionated plexus (Ao-SVC GP) improves heart rate and prognosis in vagal bradycardia with tachyarrhythmias.
methodsWe enrolled 110 patients with PVCs or PSVT and vagal bradycardia who underwent catheter ablation. Patients were randomized into the CNA group (n = 55) and the control group (n = 55). All patients underwent a conventional electrophysiological examination and ablation of PVCs or PSVT. Next, we performed Ao-SVC GP modification in patients in the CNA group. The primary endpoints included elevation of the basal HR (> 20%) and shortening of the Wenckebach cycle length (WCL) or the AH interval (> 20%).
resultsThe immediate success rate of ablation of PVCs and PSVT in both groups was 100%. Compared with those in the control group, patients in the CNA group showed significant improvement in WCL, corrected sinus node recovery time (cSNRT), mean HR, minimum HR, and DC (404.55 ± 71.80 vs. 489.27 ± 85.63; 359.15 ± 52.29 vs. 409.34 ± 59.73; 68.58 ± 8.11 vs. 56.64 ± 4.15; 46.20 ± 4.67 vs. 41.27 ± 3.25; 5.38 (4.23, 6.32) vs. 8.88 (7.17, 9.93), respectively; p < 0.05). More importantly, the incidence of syncope in the CNA group was significantly lower (p = 0.032 < 0.05), and the improvement in quality of life was greater and more extensive in the CNA group.
conclusionThe simplified right atrial Ao-SVC GP ablation effectively treats vagal bradycardia. Additionally, combining it with radiofrequency ablation for concurrent tachyarrhythmia offers a safe and innovative therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.